Products from SYNkinase
SYNkinase, headquartered in Australia, is a primary producer of research-use-only biomedical reagents, which it markets to life-science and drug-discovery researchers affiliated with Universities, Research Institutes and Industry. SYNkinase was established in 2008 by Professor Andrew Wilks and Dr Xian Bu. The founders of the company have been involved in pharmaceutical drug discovery for three decades and have extensive scientific, company and board experience.
More information at: synkinase.com
No results were found for the filter!
SAR-020106 Item number: SYN-1189-M001
Soluble in DMSO. SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC(50) of 13.3nM on the isolated human enzyme. This compound abrogates an etoposide-induced G(2) arrest with an IC(50) of 55nM in HT29 cells, and significantly enhances the cell killing of gemcitabine and SN38 by 3.0- to...
| Keywords: | SAR020106 |
| Application: | Chk1 inhibitor |
| CAS | 1184843-57-9 |
| MW: | 382,9 D |
From 250.00€ *
SB203580 Item number: SYN-1074-M005
Soluble in DMSO or ethanol. SB203580 is a specific, ATP competitive, cell-permeable inhibitor of p38 MAPK with IC(50) of 0.3-0.5µM. It is 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC(50) of 3-5µM. Target: p38 , Kinase Group: CMGC , Substrate: Serine-Threonine
| Keywords: | RWJ 64809, PB 203580 |
| Application: | P38 inhibitor |
| CAS | 152121-47-6 |
| MW: | 377,4 D |
From 66.00€ *
GW-806742X Item number: SYN-1215-M001
Soluble in DMSO. Potent protein kinase VEGFR2 inhibitor (2nm range). Binds to the pseudokinase domain of MLKL and blocks cell death by necroptosis, as well. With regards to its role in necroptosis, it is an ATP-mimetic that was shown to bind recombinant mouse MLKL pseudokinase domain, which showed inhibited...
| Keywords: | GW806742X, AC1NS7PT, AGN-PC-0LQ49Y |
| Application: | VEGFR2 inhibitor |
| CAS | 579515-63-2 |
| MW: | 573,6 D |
From 119.00€ *
SP2509 Item number: SYN-1212-M001
Soluble in DMSO. LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1...
| Keywords: | SP-2509 |
| Application: | LSD1 inhibitor |
| CAS | 1423715-09-6 |
| MW: | 437,9 D |
From 158.00€ *
Vorinostat Item number: SYN-3006-M005
Solid. Soluble in DMSO or ethanol. Almost insoluble in water. Vorinostat (SAHA, MK0683, Zolinza) inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine...
| Keywords: | SAHA, MK0683, Zolinza |
| Application: | HDAC inhibitor |
| CAS | 149647-78-9 |
| MW: | 264,3 D |
From 53.00€ *
AZD-8055 Item number: SYN-1166-M100
Soluble in DMSO or ethanol. AZD8055 is a novel ATP-competitive inhibitor of mTOR kinase activity with an IC(50) of 0.8nM. It shows excellent selectivity (~1,000-fold) against all class I phosphatidylinositol 3-kinase (PI3K) isoforms and other members of the PI3K-like kinase family. Target: mTOR , Kinase Group:...
| Keywords: | AZD8055, CCG168 |
| Application: | MTOR inhibitor |
| CAS | 1009298-09-2 |
| MW: | 465,5 D |
From 79.00€ *
KU-55933 Item number: SYN-1051-M005
Soluble in DMSO or ethanol. KU55933 is a potent and selective ATP-competitive inhibitor of ATM, with an IC(50) of 13nM and a Ki of 2.2nM. KU55933 has potential for use as a new radio- and chemo-sensitizing agent for the treatment of cancer. Target: ATM , Kinase Group: Atypical (PIKK) , Substrate: Serine-Threonine
| Keywords: | KU55933 |
| Application: | ATM inhibitor |
| CAS | 587871-26-9 |
| MW: | 395,5 D |
From 66.00€ *
SB202190 Item number: SYN-1073-M005
Soluble in DMSO or ethanol. SB202190 is potent and selective inhibitor of the p38alpha and beta, with IC(50) values of 50 and 100nM respectively. It is a powerful regulator of LPS-induced mRNAs in monocytes. Target: p38 , Kinase Group: CMGC , Substrate: Serine-Threonine
| Keywords: | SB-202190 |
| Application: | P38 alpha / beta inhibitor |
| CAS | 152121-30-7 |
| MW: | 331,4 D |
From 66.00€ *
GSK-1120212 Item number: SYN-1170-M010
Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. GSK1120212 (JTP-74057, trametinib) is a highly specific and potent MEK1 and MEK2 inhibitor with IC(50) values of 0.92nM and 1.8nM respectively. Target: MEK1 - MEK2 , Kinase Group: STE , Substrate: Serine-Threonine
| Keywords: | JTP-74057, GSK212, Trametinib |
| Application: | MEK1 / MEK2 inhibitor |
| CAS | 871700-17-3 |
| MW: | 615,4 D |
From 106.00€ *
ABT-737 Item number: SYN-1001-M001
Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. ABT-737 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate...
| Keywords: | ABT737 |
| Application: | Bcl-2 / Bcl-X(L) / Bcl-w inhibitor |
| CAS | 852808-04-9 |
| MW: | 813,4 D |
From 79.00€ *
H1152 Item number: SYN-1221-M001
Solid. Soluble in DMSO. H-1152 is a potent, specific, ATP-competitive and cell permeable ROCK inhibitor, with an IC50 of 12nM for ROCKII. H-1152 poorly inhibits PKA, PKC and myosin light chain kinase. Rho kinase (ROCK) activated by GTP-linked Rho phosphorylates targets that are involved in cytoskeletal remodelling,...
| Keywords: | (S)-4-Methyl-5-((2-methyl-1,4-diazepan-1-yl)sulfonyl)isoquinoline dihydrochloride, H1152 |
| Application: | Cell-permeable ROCK inhibitor |
| CAS | 871543-07-6 |
| MW: | 392,3 D |
From 106.00€ *
LY-294002 Item number: SYN-1108-M005
Soluble in DMSO or ethanol. LY294002 is a selective and reversible PI3K inhibitor with an IC(50) range of 0.5 - 1µM. Target: PI3K , Kinase Group: Lipid Kinase , Substrate: Lipid
| Keywords: | LY-294002 |
| Application: | PI3K inhibitor |
| CAS | 154447-36-6 |
| MW: | 307,3 D |
From 66.00€ *
Viewed